Patamostat mesylateAlternative Names: E 3123
Latest Information Update: 17 Jan 2001
At a glance
- Originator Eisai Co Ltd
- Class Benzoic acids; Small molecules
- Mechanism of Action Trypsin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Pancreatitis